Related Experiment Video

Updated: Oct 5, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Molecular mechanisms of resistance to taxanes and therapeutic implications

Franco Zunino1, Giuliana Cassinelli, Donatella Polizzi

  • 1Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, 20133, Italy

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|August 11, 2001
PubMed

Insights

Mechanisms of taxane resistance are complex, involving P-glycoprotein and altered microtubule structure. Understanding these factors is key to improving cancer treatment efficacy and designing new drugs.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Taxanes are crucial chemotherapy agents, but their efficacy is limited by drug resistance.
  • P-glycoprotein (P-gp) overexpression is a known mechanism conferring resistance to taxanes like Taxol.
  • Other resistance mechanisms involve alterations in microtubule structure and cellular responses to drug-induced damage.

Purpose of the Study:

  • To review and elucidate the multifaceted mechanisms of taxane resistance.
  • To discuss the role of cellular pathways in sensitivity to antimicrotubule agents.
  • To highlight the importance of identifying resistance factors for therapeutic advancement.

Main Methods:

  • Literature review of existing research on taxane resistance mechanisms.
  • Analysis of cellular responses to taxane-induced damage.
  • Discussion of downstream events in cell cycle and cell death pathways.

Main Results:

  • P-glycoprotein overexpression is a significant contributor to taxane resistance.
  • Changes in microtubule structure and composition reduce drug efficacy.
  • Cellular responses to cytoskeleton damage and mitotic spindle disruption play a critical role.

Conclusions:

  • Further research into taxane resistance mechanisms is essential for improving cancer therapy.
  • Identifying resistance factors will enable the design of more effective, non-cross-resistant taxane analogs.
  • Understanding these mechanisms is vital for enhancing the therapeutic efficacy of microtubule-stabilizing agents.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...